Brief: Nurix Therapeutics Announces Clearance Of Investigational New Drug Application For NX-5948 Supporting Plans To Expand Enrollment To U.S. Clinical Sites

Nurix Therapeutics

15/12/2022 21:25

Dec 15 (Reuters) - Nurix Therapeutics Inc  NRIX.O :
    * NURIX THERAPEUTICS ANNOUNCES CLEARANCE OF INVESTIGATIONAL
NEW
DRUG APPLICATION FOR NX-5948 SUPPORTING PLANS TO EXPAND
ENROLLMENT TO U.S. CLINICAL SITES
    * NURIX THERAPEUTICS INC - NX-5948 IS BEING EVALUATED IN
PATIENTS
WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES
    * NURIX THERAPEUTICS INC - PHASE 1 CLINICAL TRIAL NOW
ENROLLING
PATIENTS IN UNITED KINGDOM WITH PLANS TO EXPAND TO CLINICAL
SITES IN UNITED STATES
    * NURIX THERAPEUTICS INC - LOOK FORWARD TO ENROLLING OUR
FIRST
PATIENT IN UNITED STATES IN FIRST HALF OF 2023

Source text for Eikon:  ID:nGNXZQmX5 
Further company coverage:  NRIX.O 
 ((Reuters.Briefs@thomsonreuters.com;))